SKL-20540 is under clinical development by SK Life Science and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SKL-20540’s likelihood of approval (LoA) and phase transition for Cognitive Impairment Associated With Schizophrenia (CIAS) took place on 22 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SKL-20540 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SKL-20540 overview

SKL-20540 (SKL-15508) is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The drug candidate is administered orally. It is a small molecule that acts by targeting alpha 7-nicotinic receptor. It was under development for the treatment of Alzheimer’s disease and stable schizophrenia. 

SK Life Science overview

SK Life Science (SK Life) a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of medicinal products. The company develops technologies in the areas of biology and discovery, medicinal chemistry and pharmacology. Its biology and discovery research provide lead compound discovery and optimization that indentifies and validates signal and molecular targets. SK Life develops drugs for epilepsy, sleep disorder, neuropathic pain, Alzheimer’s dementia, anxiety, depression, and schizophrenia. The company’s technical expertise includes continuous flow process and chiral chemistry. It develops drugs through partnerships with universities, government organizations, pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.

Quick View SKL-20540 LOA Data

Report Segments
  • Innovator
Drug Name
  • SKL-20540
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.